These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 22123383

  • 1. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
    Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ, Reshef A.
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
    [Abstract] [Full Text] [Related]

  • 2. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A.
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [Abstract] [Full Text] [Related]

  • 3. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M.
    Int Arch Allergy Immunol; 2015 Nov; 168(1):44-55. PubMed ID: 26556097
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.
    Baş M.
    Expert Rev Clin Immunol; 2012 Nov; 8(8):707-17. PubMed ID: 23167682
    [Abstract] [Full Text] [Related]

  • 5. Icatibant for the treatment of hereditary angioedema.
    Cole SW, Lundquist LM.
    Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
    [Abstract] [Full Text] [Related]

  • 6. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).
    Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W.
    J Allergy Clin Immunol; 2007 Jun; 119(6):1497-503. PubMed ID: 17418383
    [Abstract] [Full Text] [Related]

  • 7. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H, Reshef A, Aberer W, Caballero T, McCarthy L, Hao J, Nothaft W, Schranz J, Bernstein JA, Li HH.
    J Allergy Clin Immunol Pract; 2017 Jun; 5(6):1671-1678.e2. PubMed ID: 28601641
    [Abstract] [Full Text] [Related]

  • 8. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
    Maurer M, Longhurst HJ, Fabien V, Li HH, Lumry WR.
    Allergy Asthma Proc; 2014 Jun; 35(5):377-81. PubMed ID: 25198193
    [Abstract] [Full Text] [Related]

  • 9. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
    Malbrán A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A, Hébert J, Gleich GJ, Hurewitz D, Jacobson KW, Bernstein JA, Khan DA, Kirkpatrick CH, Resnick D, Li H, Fernández Romero DS, Lumry W.
    Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
    [Abstract] [Full Text] [Related]

  • 10. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
    Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT.
    N Engl J Med; 2010 Aug 05; 363(6):532-41. PubMed ID: 20818888
    [Abstract] [Full Text] [Related]

  • 11. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema.
    Greve J, Hoffmann TK, Schuler P, Lang S, Chaker A, Bas M.
    Int J Dermatol; 2011 Oct 05; 50(10):1294-5. PubMed ID: 21950301
    [Abstract] [Full Text] [Related]

  • 12. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study.
    Zanichelli A, Bova M, Coerezza A, Petraroli A, Triggiani M, Cicardi M.
    Allergy; 2012 Aug 05; 67(8):1074-7. PubMed ID: 22686628
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.
    Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtułowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Bernstein JA.
    J Allergy Clin Immunol; 2009 Oct 05; 124(4):801-8. PubMed ID: 19767078
    [Abstract] [Full Text] [Related]

  • 14. Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.
    Prescrire Int; 2010 Nov 05; 19(110):245-7. PubMed ID: 21284353
    [Abstract] [Full Text] [Related]

  • 15. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
    Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbrán A.
    Allergy; 2014 Mar 05; 69(3):305-14. PubMed ID: 24438203
    [Abstract] [Full Text] [Related]

  • 16. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Hide M, Fukunaga A, Maehara J, Eto K, Hao J, Vardi M, Nomoto Y.
    Arerugi; 2018 Mar 05; 67(2):139-147. PubMed ID: 29553114
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series.
    Bas M, Greve J, Stelter K, Bier H, Stark T, Hoffmann TK, Kojda G.
    Ann Emerg Med; 2010 Sep 05; 56(3):278-82. PubMed ID: 20447725
    [Abstract] [Full Text] [Related]

  • 18. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
    Otani IM, Lumry WR, Hurwitz S, Li HH, Craig TJ, Holtzman NS, Iandoli MI, Tucker J, Riedl MA, Zuraw BL, Banerji A.
    J Allergy Clin Immunol Pract; 2017 Sep 05; 5(2):442-447.e1. PubMed ID: 27818136
    [Abstract] [Full Text] [Related]

  • 19. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.
    Krause K, Metz M, Zuberbier T, Maurer M, Magerl M.
    J Dtsch Dermatol Ges; 2010 Apr 05; 8(4):272-4. PubMed ID: 19758369
    [Abstract] [Full Text] [Related]

  • 20. The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.
    Longhurst HJ, Aberer W, Bouillet L, Caballero T, Maurer M, Fabien V, Zanichelli A, IOS Study Group.
    Eur J Emerg Med; 2016 Jun 05; 23(3):224-7. PubMed ID: 27116379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.